牛牛AI助理已提取核心訊息
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-3 effective by 5:00 p.m. Eastern Time on January 19, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, as amended, was submitted through a correspondence dated January 17, 2024. The company's legal representative, Alex Dinur of Lowenstein Sandler LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.
Altamira Therapeutics Ltd. has officially requested the United States Securities and Exchange Commission (SEC) to declare its Registration Statement on Form F-3 effective by 5:00 p.m. Eastern Time on January 19, 2024. The request, made in accordance with Rule 461 under the Securities Act of 1933, as amended, was submitted through a correspondence dated January 17, 2024. The company's legal representative, Alex Dinur of Lowenstein Sandler LLP, is the point of contact for the SEC to confirm the effectiveness of the Registration Statement or to address any inquiries.
Altamira Therapeutics Ltd.已正式要求美國證券交易委員會（SEC）在東部時間2024年1月19日下午5點之前宣佈其F-3表格的註冊聲明生效。該請求是根據經修訂的1933年《證券法》第461條提出的，是通過2024年1月17日的信函提交的。該公司的法定代表人，洛文斯坦·桑德勒律師事務所的亞歷克斯·迪努爾是美國證券交易委員會的聯繫人，負責確認註冊聲明的有效性或處理任何查詢。
Altamira Therapeutics Ltd.已正式要求美國證券交易委員會（SEC）在東部時間2024年1月19日下午5點之前宣佈其F-3表格的註冊聲明生效。該請求是根據經修訂的1933年《證券法》第461條提出的，是通過2024年1月17日的信函提交的。該公司的法定代表人，洛文斯坦·桑德勒律師事務所的亞歷克斯·迪努爾是美國證券交易委員會的聯繫人，負責確認註冊聲明的有效性或處理任何查詢。
有用
沒用
該公告為獨立文件：